TABLE 5.
Clinical trials related to anti‐hyperglycemic drugs
| Study | Registry identifier | Title | Interventions |
|---|---|---|---|
| 1 | NCT04542213 | Dipeptidyl peptidase‐4 inhibitor (Dpp4i) for the control of hyperglycemia in patients with COVID‐19 (Covid19Dpp4i) | Linagliptin, insulin |
| 2 | NCT04371978 | Efficacy and safety of dipeptidyl peptidase‐4 inhibitors in diabetic patients with established COVID‐19 | Linagliptin, insulin |
| 3 | NCT04604223 | Effect of pioglitazone on t2dm patients with COVID‐19 (PIOQ8) | Pioglitazone |
| 4 | NCT04535700 | Clinical trial of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID‐19 | Pioglitazone |
| 5 | NCT04625985 | Metformin glycinate, treatment of patients with COVID‐19 and severe acute respiratory syndrome secondary to SARS‐CoV‐2. (DMMETCOV19‐2) | Metformin glycinate |
| 6 | NCT04473274 | GlitazOne treatment for coronavirus hypoxia, a safety and tolerability open label with matching cohort pilot study (GOTCHA) | Pioglitazone |
| 7 | NCT04510194 | Outpatient treatment of SARS‐CoV‐2 With ivermectin, fluvoxamine, and metformin (COVID‐19) | Metformin, metformin+fluvoxamine, and metformin+ivermectin |